← Leaderboards
Vineet Gupta
Washington University
$8,266,585
Attributed
$13,731,786
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,731,786 · 8
By mechanism
R01$12,935,076 · 6
K01$709,210 · 1
R03$87,500 · 1
Top collaborators
- Roberto Irenardo Vazquez Padron7 shared
- David G Denardo5 shared
- Sanja Sever5 shared
- Jochen Reiser4 shared
- Timothy B Niewold2 shared
- Yan-Ting E. Shiu2 shared
Most similar at Washington University
Same institution · by research overlap
- Andrey S. Shaw$11,736,578
- Feng Chen$14,745,479
- Kathryn A Yamada$2,920,414
- Justin Sonnenburg$17,296,190
- Eric T Choi$1,929,407
Others in their field
Top investigators on “Integrins”
- Timothy A Springer · Boston Children'S Hospital$50,095,849
- David A Cheresh · Scripps Research Institute$28,587,859
- Mark Howard Ginsberg · University Of California, San Diego$28,221,483
- Martin A. Schwartz · Yale University$23,274,443
- M. Amin Arnaout · Massachusetts General Hospital$23,064,887
- Edward Franklin Plow · Cleveland Clinic Foundation$22,902,830
Research focus
IntegrinsGeneticFutureIn VivoNovel TherapeuticsInjurySmall MoleculeInflammationCellsItgam GeneInfiltrationInflammatoryBaseAgonistMolecularLeukocytesKidney DiseasesTargeted TreatmentIn VitroKidneyFunctional DisorderSignal TransductionMediatingTranslating
Grant awards (40)
Translating oral CD11b agonist as a novel therapeutic for lupus nephritis$721,611
R01 · FY2025 · DK · contact PI
Integrin Activation to Prevent Early Arteriovenous Fistula Failure in End-stage Renal Disease Patients$469,978
R01 · FY2025 · DK
Translating oral CD11b agonist as a novel therapeutic for lupus nephritis$746,829
R01 · FY2024 · DK · contact PI
Integrin Activation to Prevent Early Arteriovenous Fistula Failure in End-stage Renal Disease Patients$557,622
R01 · FY2024 · DK
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy$422,422
R01 · FY2024 · CA
Role of beta2 integrin in lupus nephritis$461,458
R01 · FY2023 · DK · contact PI
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy$435,761
R01 · FY2023 · CA
Role of beta2 integrin in lupus nephritis$14,724
R01 · FY2023 · DK · contact PI
Role of beta2 integrin in lupus nephritis$477,515
R01 · FY2022 · DK · contact PI
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy$435,761
R01 · FY2022 · CA
Role of beta2 integrin in lupus nephritis$478,809
R01 · FY2021 · DK · contact PI
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy$444,655
R01 · FY2021 · CA
Role of beta2 integrin in lupus nephritis$480,065
R01 · FY2020 · DK · contact PI
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy$458,317
R01 · FY2020 · CA
Role of beta2 integrin in lupus nephritis$509,784
R01 · FY2019 · DK · contact PI
Novel Anti-Proteinuric Strategies Targeting Podocytes$460,320
R01 · FY2019 · DK · contact PI
Novel Anti-Proteinuric Strategies Targeting Podocytes$447,180
R01 · FY2018 · DK · contact PI
Novel Anti-Proteinuric Strategies Targeting Podocytes$447,180
R01 · FY2017 · DK · contact PI
Podocyte-based HCS assays for discovering therapeutics against kidney diseases$393,750
R01 · FY2017 · DK · contact PI
Novel Anti-Proteinuric Strategies Targeting Podocytes$463,720
R01 · FY2016 · DK · contact PI
Podocyte-based HCS assays for discovering therapeutics against kidney diseases$393,750
R01 · FY2016 · DK · contact PI
Leukadherins as novel compounds for treating restenosis$461,432
R01 · FY2015 · HL
Podocyte-based HCS assays for discovering therapeutics against kidney diseases$407,500
R01 · FY2015 · DK · contact PI
Novel Small Molecule Agonists of Integrin CD11b/CD18 as Anti-Inflammatory Agents$229,500
R01 · FY2015 · DK · contact PI
Leukadherins as novel compounds for treating restenosis$374,850
R01 · FY2014 · HL
Novel Small Molecule Agonists of Integrin CD11b/CD18 as Anti-Inflammatory Agents$229,500
R01 · FY2014 · DK · contact PI
Leukadherins as novel compounds for treating restenosis$85,960
R01 · FY2014 · HL
Leukadherins as novel compounds for treating restenosis$364,140
R01 · FY2013 · HL
Novel Small Molecule Agonists of Integrin CD11b/CD18 as Anti-Inflammatory Agents$221,468
R01 · FY2013 · DK · contact PI
Leukadherins as novel compounds for treating restenosis$382,500
R01 · FY2012 · HL
Novel Small Molecule Agonists of Integrin CD11b/CD18 as Anti-Inflammatory Agents$210,450
R01 · FY2012 · DK · contact PI
Novel Small Molecule Agonists of Integrin CD11b/CD18 as Anti-Inflammatory Agents$19,050
R01 · FY2012 · DK · contact PI
Novel Small Molecule Agonists of Integrin CD11b/CD18 as Anti-Inflammatory Agents$227,515
R01 · FY2011 · DK · contact PI
Beta2 Integrin Activation and Signaling$54,000
K01 · FY2010 · DK · contact PI
Beta2 Integrin Activation and Signaling$127,630
K01 · FY2008 · DK · contact PI
Beta2 Integrin Activation and Signaling$135,540
K01 · FY2007 · DK · contact PI
Beta2 Integrin Activation and Signaling$131,490
K01 · FY2006 · DK · contact PI
Beta2 Integrin Activation and Signaling$130,680
K01 · FY2005 · DK
HTS Assay for Discovery:Small Molecule Regulators (RMI)$87,500
R03 · FY2005 · NS
Beta2 Integrin Activation and Signaling$129,870
K01 · FY2004 · DK